Navigation Links
Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders
Date:12/6/2008

ing in the mouth, and rash-like spots on the skin.

If left untreated, thrombocytopenia can become a life-threatening condition when blood platelet counts fall below 5,000 microliters because the risk of serious hemorrhaging (excessive bleeding) increases. Normal blood platelet counts are typically between 150,000 to 450,000 microliters in adults. Treatment for thrombocytopenia is dependent on the cause and severity of the condition and can include drug therapy, splenectomy (removal of spleen, whose function is to breakdown blood cells such as platelets), and platelet transfusions.

A Prospective Randomized Study Comparing Rituximab andDexamethasone Versus

Dexamethasone Alone in ITP: Results of Final Analysis and Long-Term Follow-Up

[Abstract #1]

Francesco Zaja, MD, Clinica Ematologica DIRM AOUD, Udine, Italy

This multicenter phase III study is the first to prospectively determine that adding the immunotherapy drug rituximab to dexamethasone (a steroid that is a standard therapy for ITP) is safe and effective in adult patients with previously untreated idiopathic thrombocytopenic purpura (ITP). The results of this study indicate that this treatment regimen could be an effective option prior to splenectomy for some patients as well as a possible cure for others.

In this study, patients were randomized to one of two treatment regimens: oral dexamethasone alone (40 mg) given on the first four days of treatment or the same regimen of dexamethasone plus rituximab given as an intravenous infusion (375 mg/m^2) once a week for four weeks. Some patients in the dexamethasone-only arm who failed to achieve a sustained response and had platelet counts of less than or equal to 20 x 10^9/L following 30 days of therapy up to the end of six months received a salvage (rescue) treatment of r
'/>"/>

SOURCE American Society of Hematology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Cayenne Medical, Inc., a private sports medicine device ... System, its second generation device for treatment of traumatic ... the 2011 American Orthopaedic Society for Sports Medicine Annual ... Tal David, MD, orthopedic sports medicine specialist, San ...
... June 29, 2011 Suneva Medical, a privately-held ... of its core aesthetics injectable business with approval ... its long lasting dermal filler for nasolabial folds ... patients a unique, long-lasting treatment, Bellafill provides physicians ...
Cached Medicine Technology:Cayenne Medical, Inc. Launches CrossFix® II Meniscal Repair System 2Suneva Medical Announces Canadian Approval of Bellafill™ 2
(Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
(Date:7/9/2014)... (July 8, 2014) Researchers from Montefiore Medical ... Medicine of Yeshiva University will present new findings ... July 12 July 17 in Copenhagen, Denmark. Data ... could prompt transition from cognitive normality to mild cognitive ... Einstein Aging Study , established in 1980 to ...
(Date:7/9/2014)... of the most important organs in the human body. ... food properly this is its synthesis function ... this is its detoxification function. Lack of exercise ... damage the liver. The resulting diseased cells can lead ... liver failure. According to the German Liver Foundation, over ...
(Date:7/9/2014)... July 9, 2014 A study published in the ... Koninck and Robert Bonin, two researchers at Universit Laval, ... using a new method that involves rekindling pain so ... lead to novel means to alleviate chronic pain. , ... Laval and Institut universitaire en sant mentale de Qubec ...
(Date:7/8/2014)... Department of Defense,s Defense Advanced Research Projects Agency ... to $2.5 million to develop an implantable neural ... neurons within the brain to help restore memory, ... builds on the understanding that memory is a ... the brain encode information, store it and retrieve ...
Breaking Medicine News(10 mins):Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Discovery of a new means to erase pain 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3
... 28 Ronald McDonald House Charities of,the New York ... local graduating high school seniors. Students in the New,York, ... an application at www.rmhc.org or call 1-866-851-3994. ... "The RMHC U.S. Scholarship Program ...
... has halved the number of infants born with Down,s ... birth by 30%, according to a study published on ... Australia and New Zealand, are trying to introduce national ... variety of problems because of a lack of consensus ...
... appear even in the presence of disinfecting solutions , , THURSDAY, ... lens storage cases, say Israeli researchers who found at least ... 16 people. , The tests of contact lens disinfection solution ... a known cause of severe corneal infections -- was the ...
... The Committee for Human,Medicinal Products (CHMP) has ... dosing of 800 mg PREZISTA(R) (darunavir) with ... treatment-naive adults (those who,have never taken HIV ... by Tibotec Pharmaceuticals, and Tibotec, a division ...
... Nov. 27 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc.,(NYSE: ... and medical device,research and development outsourcing company with ... Edward Hu, the Company,s Chief Operating,Officer, will present ... Wednesday, December 3, 2008, at 12:00 pm Eastern ...
... 26 /PRNewswire-USNewswire/ -- The Pennsylvania Department of ... outpatient, emergency and non-emergency admissions to Commonwealth Medical Center, ... , The department said ... management addresses non-compliance with licensing standards which pose a ...
Cached Medicine News:Health News:Ronald McDonald House Charities(R) of the New York Tri-State Area to Award Over $500,000 in Scholarships to Graduating High School Seniors 2Health News:New screening halves the number of children born with Down syndrome 2Health News:Contact Lens Cases Often Contaminated 2Health News:European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1 2Health News:European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1 3Health News:European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1 4Health News:WuXi PharmaTech to Present at 20th Annual Piper Jaffray Healthcare Conference 2
... nebulizer achieves optimum lung penetration for maximum ... is 1.04-1.10 µ at 6-8 LPM. Latex-free ... ,As the world leader in airway ... assurance of proven technology by offering top ...
... OMNI~NEB delivers breakthrough continuous low-flow nebulizer ... precise nozzle technology allows for optimal ... or without Heliox). OMNI~NEB takes on ... both routine and critical care situations. ...
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
... Portex® medication nebulizers offer a spill-proof ... up to a 45° angle. All medical ... ,A wide variety of configurations are available., ... latex-free. , ,Portex® medication nebulizers feature ...
Medicine Products: